Ana H.
- Country
- Germany
- Department
- 2048"Medizinische Klinik I, Transplantationszentrum
Research Overview
- A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of RO7434656, an Antisense Inhibitor of Complement Factor B, in Patients with Primary IgA Nephropathy at High Risk of Progression
- Evaluation of Iptacopan in Combination with Standard-of-Care for Efficacy and Safety in Adult Patients with Active Lupus Nephritis Class III-IV, +/- V
Data & Insights
Has run more than one trial at 3 of 56 partner sites.
Specializations
Nephrology
The investigator specializes in treating complex renal disorders, with particular emphasis on autoimmune kidney diseases and their progressive manifestations.
- Primary IgA Nephropathy
- Lupus Nephritis Class III-IV
Their research focuses on proteinuria management and innovative therapeutic approaches in glomerular diseases.
Autoimmune Disorders
The investigator concentrates on the treatment of systemic autoimmune conditions affecting renal function and their various manifestations.
- Complement System Modulation
- Immunoglobulin-Related Disorders
Their work involves evaluating novel therapeutic agents targeting specific immune pathways in kidney diseases.
Clinical Therapeutics
The investigator explores innovative treatment approaches for patients with progressive kidney diseases.
- Complement Factor Inhibition
- Proteinuria Management
- Renal Response Assessment
Their expertise includes evaluating urine protein-to-creatinine ratio as a measure of treatment efficacy.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.